MINI FUTURE OPTIONSSCHEIN PUT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 15:35:15 2024-07-08 EDT | After market 15:59:50 | |||
| 6.04 EUR | -10.65% |
|
6.085 | +0.75% |
| Current month | -13.27% | ||
| 1 month | +4.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 6.04 | -10.65% |
| 24-07-05 | 6.76 | -2.17% |
| 24-07-04 | 6.91 | -4.82% |
| 24-07-03 | 7.26 | +7.24% |
| 24-07-02 | 6.77 | -2.87% |
Real-time Boerse Frankfurt Warrants
Last update July 08, 2024 at 03:35 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DQ382N |
| ISIN | DE000DQ382N3 |
| Date issued | 2024-06-07 |
| Strike | 545.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.712 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.67 € |
|---|---|
| Lowest since issue | 5.58 € |
| Spread | 0.03 € |
| Spread % | 0.49% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
471
USD
Spread / Average Target
-0.75%
- Stock Market
- Certificates
- Certificat
